Inovio's shares, by contrast, appear to have simply followed the broader biotech industry lower last month, evinced by the poor performance of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) in October. Inovio took a particularly hard …
Inovio Pharmaceuticals, Inc. INO announced that it has initiated the second study on its preventive Zika vaccine, GLS-5700, in Puerto Rico. The company’s shares gained 4.6% on the news. The placebo-controlled, double-blind study is …
Inovio Pharmaceuticals (NASDAQ: INO), a clinical-stage DNA vaccine company, lost 10% of its value in December, according to data from S&P Global Market Intelligence. As the company maintained radio silence last month in terms …
Shares of the clinical-stage biotech Inovio Pharmaceuticals (NASDAQ: INO) gained as much as 38% today due to a positive early-stage readout for its experimental HIV vaccine called Pennvax-GP. Digging into the details, the company …
Shares of Inovio Pharmaceuticals Inc closed the previous trading session at 7.88 down -0.11 -1.38% with 1,631,705 …
The vaccine is still in Phase I testing. While the positive results are certainly good fundamental news for Inovio stock, a short squeeze is likely responsible for some of the big move. Inovio’s short interest has been steadily declining in the …
A quick analysis of Inovio Pharmaceuticals' (NASDAQ: INO) stock performance history shows plenty of twists and turns -- from the company's early biomedical days to its recent advances in developing a Zika virus vaccine. But this chart …
According to S&P; Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit decline wasn't the result of a negative clinical …